Department of Histopathology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, Punjab, 160012, India.
Department of Immunopathology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, Punjab, 160012, India.
Mol Diagn Ther. 2020 Apr;24(2):153-173. doi: 10.1007/s40291-020-00447-w.
Breast cancer is the second most common cause of deaths reported in women worldwide, and therefore there is a need to identify breast cancer patients at an early stage as timely diagnosis would help in effective management and appropriate monitoring of patients. Nevertheless, it is challenging to achieve these goals due to the lack of a specific biomarker for early detection and monitoring in breast cancer. Recently, microRNAs (miRNAs) have emerged as master regulators of the molecular pathways highlighted in different tumors leading to progression in malignancies. With the rapid advancements in molecular research, the potential to use miRNAs as prognostic and diagnostic biomarkers in breast cancer has been highlighted, as their dysregulation is directly associated with breast cancer progression and metastasis. The ease of detection and long-term stability of circulating miRNAs in blood makes them a promising candidate for non-invasive breast cancer biomarkers.
乳腺癌是全球女性报告的第二大常见死因，因此需要尽早识别乳腺癌患者，因为及时诊断有助于有效管理和适当监测患者。然而，由于缺乏用于早期检测和监测乳腺癌的特异性生物标志物，因此实现这些目标具有挑战性。最近，microRNAs (miRNAs) 已成为不同肿瘤中突出的分子途径的主要调节剂，导致恶性肿瘤的进展。随着分子研究的快速发展，已经强调了 miRNAs 作为乳腺癌预后和诊断生物标志物的潜力，因为它们的失调与乳腺癌的进展和转移直接相关。循环 miRNA 在血液中检测方便且长期稳定，使其成为非侵入性乳腺癌生物标志物的有前途的候选物。
